Inhibition of cGMP-metabolizing PDEs as target for cognitive enhancement

por Rosenbrock, Holger
Publicado 2015

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia

por Rosenbrock, Holger, Desch, Michael, Wunderlich, Glen
Publicado 2023

Effects of the mGlu2/3 receptor agonist LY379268 on two models of disturbed auditory evoked brain oscillations in mice

por Dormann, Oana-Daniela, Schuelert, Niklas, Rosenbrock, Holger
Publicado 2023

A comprehensive analysis of auditory event‐related potentials and network oscillations in an NMDA receptor antagonist mouse model using a novel wireless recording technology

por Schuelert, Niklas, Dorner‐Ciossek, Cornelia, Brendel, Michael, Rosenbrock, Holger
Publicado 2018

PM537. GPR52 agonists show pro-cognitive properties

por von Heimendahl, Moritz, Arban, Roberto, Deiana, Serena, Hobson, Scott, Rosenbrock, Holger, Schülert, Niklas
Publicado 2016

Targeting the dopamine D(1) receptor or its downstream signalling by inhibiting phosphodiesterase‐1 improves cognitive performance

por Pekcec, Anton, Schülert, Niklas, Stierstorfer, Birgit, Deiana, Serena, Dorner‐Ciossek, Cornelia, Rosenbrock, Holger
Publicado 2018

S31. ENHANCEMENT OF SYNAPTIC PLASTICITY BY COMBINATION OF PDE2 AND PDE9 INHIBITION PRESUMABLY VIA PRE- AND POST-SYNAPTIC MECHANISMS

por Rosenbrock, Holger, Kroker, Katja, Stierstorfer, Birgit, Hobson, Scott, Arban, Roberto, Dorner-Ciossek, Cornelia
Publicado 2020

M181. DEVELOPMENTAL PROGRESSION OF INTERNEURON NETWORK DEFICITS IN A 15Q13.3 MICRODELETION MOUSE MODEL – A GLIMPSE ON ADOLESCENT PRIMING FOR SCHIZOPHRENIA?

por Funk, Marzieh, Jaeger, Stefan, Schülert, Niklas, Dorner-Ciossek, Cornelia, Rosenbrock, Holger, Mack, Volker
Publicado 2020

PT745. Targeting the dopamine 1 receptor or its downstream signalling by inhibiting phosphodiesterase-1 improves cognitive performance

por Pekcec, Anton, Schülert, Niklas, Giovannini, Riccardo, Pfau, Roland, Stierstorfer, Birgit, Hobson, Scott, Rosenbrock, Holger
Publicado 2016

S141. TRANSGENIC OVEREXPRESSION OF THE TYPE III ISOFORM OF NEUREGULIN 1 IN MICE INDUCES ABNORMALITIES ON AUDITORY EVENT RELATED EEG BIOMARKERS RELATED TO SCHIZOPHRENIA

por Rosenbrock, Holger, Nissen, Wiebke, Arban, Roberto, Moritz, Rossner, Markus, Schwab, Dorner-Ciossek, Cornelia, Schülert, Niklas
Publicado 2018

T178. MICROPIPETTE-GUIDED DRUG ADMINISTRATION (MDA) METHOD AS A NOVEL PHARMACOLOGICAL TREATMENT METHOD IN MICE: PRECLINICAL VALIDATION USING RISPERIDONE IN THE MATERNAL IMMUNE ACTI...

por Scarborough, Joseph, Müller, Flavia, Dorner-Ciossek, Cornelia, Arban, Roberto, Rosenbrock, Holger, Meyer, Urs, Richetto, Juliet
Publicado 2020

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 42580...

por Schultheis, Christian, Rosenbrock, Holger, Mack, Salome Rebecca, Vinisko, Richard, Schuelert, Niklas, Plano, Andrea, Süssmuth, Sigurd D.
Publicado 2022

Symptomatic and preventive effects of the novel phosphodiesterase-9 inhibitor BI 409306 in an immune-mediated model of neurodevelopmental disorders

por Scarborough, Joseph, Mattei, Daniele, Dorner-Ciossek, Cornelia, Sand, Michael, Arban, Roberto, Rosenbrock, Holger, Richetto, Juliet, Meyer, Urs
Publicado 2021

Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled...

por Moschetti, Viktoria, Desch, Michael, Goetz, Sophia, Liesenfeld, Karl-Heinz, Rosenbrock, Holger, Kammerer, Klaus-Peter, Wunderlich, Glen, Wind, Sven
Publicado 2017

Effects of Cytochrome P450 3A4 Induction and Inhibition on the Pharmacokinetics of BI 425809, a Novel Glycine Transporter 1 Inhibitor

por Desch, Michael, Wunderlich, Glen, Goettel, Markus, Goetz, Sophia, Liesenfeld, Karl-Heinz, Chan, Tom S., Rosenbrock, Holger, Sennewald, Regina, Link, Jasmin, Keller, Sascha, Wind, Sven
Publicado 2021

Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression

por Hesse, Raphael, Lausser, Ludwig, Gummert, Pauline, Schmid, Florian, Wahler, Anke, Schnack, Cathrin, Kroker, Katja S., Otto, Markus, Tumani, Hayrettin, Kestler, Hans A., Rosenbrock, Holger, von Arnim, Christine A. F.
Publicado 2017

A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale

por Keefe, Richard S. E., Woods, Scott W., Cannon, Tyrone D., Ruhrmann, Stephan, Mathalon, Daniel H., McGuire, Philip, Rosenbrock, Holger, Daniels, Kristen, Cotton, Daniel, Roy, Dooti, Pollentier, Stephane, Sand, Michael
Publicado 2020

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies

por Rosenbrock, Holger, Desch, Michael, Kleiner, Oliver, Dorner‐Ciossek, Cornelia, Schmid, Bernhard, Keller, Sascha, Schlecker, Christina, Moschetti, Viktoria, Goetz, Sophia, Liesenfeld, Karl‐Heinz, Fillon, Gwenaelle, Giovannini, Riccardo, Ramael, Steven, Wunderlich, Glen, Wind, Sven
Publicado 2018